CG Oncology, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CG Oncology, Inc. - overview
Established
2010
Location
Irvine, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2010 by co-founders Alex Yeung and Paul DeRidder, MD, CG Oncology, Inc. , formerly known as Cold Genesys, Inc. , operates as a clinical-stage biopharmaceutical company that develops immunotherapeutic drugs for oncolytic studies for the treatment of patients with advanced cancer. In January 2024, CG Oncology, Inc.
raised USD 380 million in an IPO, selling 20 million shares at USD 19 per share, above the expected USD 16–18 range, on the Nasdaq Global Select Market under the ticker symbol "CGON. " CG Oncology, Inc. has granted the underwriters a 30-day option to purchase up to an additional 3 million shares of common stock as part of the listing. Ally Bridge Group retained a 3.
9% minority stake, Decheng Capital retained a 7. 2% minority stake, Foresite Capital retained a 4. 4% minority stake, Kissei Pharmaceutical Co. , Ltd.
retained a 5. 6% minority stake, ORI Capital retained a 7. 8% minority stake, and TCG Crossover Management retained a 4. 4% minority stake in the company, respectively.
As of 2024, the company is led by its CEO, Arthur Kuan. The company provides a wide range of clinical biopharmaceutical products, such as cretostimogene grenadenorepvec, an investigational-engineered oncolytic immunotherapy. This therapy is in clinical trials for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) both as a monotherapy and in combination with other treatments.
Current Investors
ORI Capital, Perseverance Capital, Oria Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.cgoncology.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
CG Oncology, Inc. - timeline of key events
CG Oncology, Inc. - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue (USD) | 10,358,000 | 191,000 | - | - | - |
| % Revenue Growth (YoY) | - | (98.2%) | - | - | - |
| EBITDA (USD) | (12,585,000) | (35,187,000) | - | - | - |
| Operating Income (USD) | (12,606,000) | (35,246,000) | - | - | - |
| Operating Margin | (121.7%) | (18453.4%) | - | - | - |
| % EBITDA Margin | (121.5%) | (18422.5%) | - | - | - |
| NET Income (USD) | (12,839,000) | (35,443,000) | - | - | - |
| % Net Margin | (124.0%) | (18556.5%) | - | - | - |
CG Oncology, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | CG Oncology, Inc. | - |
Displaying 1 - 1 of 1
CG Oncology, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.